Immunovia Interim Report, January-September 2019

“The Commercial Test Model” study is going to deliver results according to plan at year-end 2019, and IMMray™ PanCan-d is thus on track for sales start in Q3 2020. The Key Opinion Leader networks continue to grow and provide the company with world-leading expertise, both in the main focus area of pancreatic cancer, with a total estimated market of USD 4.4 billion, as well as in the discovery projects for lung cancer and autoimmunity, with multiple larger total markets.

“The third quarter was an exciting and eventful time for us at Immunovia following the groundbrea-king results of the IMMray™ PanCan-d optimization study. We began the quarter with the first in a series webinar to mark the milestones that Immunovia has reached as we move towards the com-mercialization of IMMray™ PanCan-d. This first webinar outlined the extraordinary results achieved in the optimization study representing all of our three target risk groups, Familiar/hereditary, New Onset Diabetics as well as Early Symptoms.

At Immunovia, we remain fully committed and focused on IMMray™ PanCan-d. Bringing IMMray™ PanCan–d to market and dominating the market for early detection of pancreatic cancer in the foreseeable future is a fantastic opportunity with a total estimated market potential of USD 4.4 bil-lion in the US and Europe alone, and is now within our reach. By meeting an unmet need, Immuno-via will contribute to save many lives.

We continue to be on-schedule and work intensely for all preparations for our planned launch of IMMray™ PanCan-d in Q3 2020, as well as, forward progress with Immunovia’s lung cancer and RA processes.” 

Excerpt from the CEO Mats Grahn’s comment on the report.

Key Indicators

SEK thousand unless otherwise stated 2019 Jul-Sep 2018 Jul-Sep 2019 Jan-Sep 2018 Jan-Sep 2018 Full Year
Net sales 92 85 311 241 333
Operating earnings -27 927 -17 344 -84 666 -61 952 -87 708
Earnings before tax -25 625 -17 403 -81 903 -60 876 -86 531
Net earnings -25 625 -17 403 -81 906 -60 883 -86 538
Earnings per share before dilution (SEK) -1.31 -0.89 -4.19 -3.34 -4.67
Earnings per share after dilution (SEK) -1.31 -0.89 -4.19 -3.34 -4.67
Equity ratio (%) 87 97 87 97 97
Number of shares at the end of the period 19 654 853 19 531 353 19 654 853 19 531 353 19 531 353

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiaries Immunovia Incentive AB, Immunovia Inc. and Immunovia GmbH.

Immunovia invites to a teleconference (in English) for investors, analysts and media on November 8th between 3:00 p.m. – 4:00 p.m. CET. Immunovia will publish the company’s interim report for the period January-September 2019 on Friday, November 8th, 2019 at 2:00 p.m. CET.

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January-September 2019 Report followed by a Q&A session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below:

BE: +3226200547
CH: +41225805976
DE: +4969222220380
DK: +4578150107
FR: +33170750718
NL: +31207219496
NO: +4723500236
SE: +46850558352
UK: +443333009035
US: +18338230590

Weblink

https://tv.streamfabriken.com/immunovia-q3-2019

For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia

Email: julie.silber@immunovia.com

Tel: +46 7 93 486 277

There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

About Immunovia 
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###

About Us

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

Subscribe

Documents & Links